Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)

Journal of Clinical Oncology

Volumn 34, Issue 25, 2016, Pages 3047-3053

  Niedzwiecki, Donna ^a   Frankel, Wendy L ^a   Venook, Alan P ^a   Ye, Xing ^a   Friedman, Paula N ^a   Goldberg, Richard M ^a   Mayer, Robert J ^a   Colacchio, Thomas Anthony ^a   Mulligan, Jude Marie ^a   Davison, Timothy S ^a   O'Brien, Eamonn ^a   Kerr, Peter ^a   Johnston, Patrick G ^a   Kennedy, Richard D ^a   Harkin, D Paul ^a   Schilsky, Richard L ^a   Bertagnolli, Monica M ^a   Warren, Robert S ^a   Innocenti, Federico ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDRECOLOMAB; MONOCLONAL ANTIBODY;

ADULT; BIOASSAY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLDX ASSAY; COLON CANCER; CONFERENCE PAPER; FEMALE; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE INTERVAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; TREATMENT OUTCOME; TUMOR LOCALIZATION; AGED; COHORT ANALYSIS; COLONIC NEOPLASMS; DISEASE FREE SURVIVAL; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR RECURRENCE;

AGED; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III AS TOPIC; COHORT STUDIES; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84983528159     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.4699     Document Type: Conference Paper

References (23)

1. Edge S, Byrd D, Compton C, et al. AJCC Cancer Staging Manual (ed 7). New York, NY, Springer, 2010
2. Benson AB III, Schrag D, Somerfield MR, et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408-3419, 2004
3. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology, Colon Cancer v2.2015. http://www.nccn.org
4. Van Cutsem E, Oliveria J, ESMO Guidelines Working Group: Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 20:49-50, 2009 (suppl 4)
5. Vicuna B, Benson AB III: Adjuvant therapy for stage II colon cancer: Prognostic and predictive markers. J Natl Compr Canc Netw 5:927-936, 2007
6. Kennedy RD, Bylesjo M, Kerr P, et al: Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffinembedded tissue. J Clin Oncol 29:4620-4626, 2011
7. Venook AP, Niedzwiecki D, Lopatin M, et al: Biologic determinants of tumor recurrence in stage II colon cancer: Validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol 31:1775-1781, 2013
8. Salazar R, Roepman P, Capella G, et al: Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 29: 17-24, 2011
9. Agesen TH, Sveen A, Merok MA, et al: ColoGuideEx: A robust gene classifier specific for stage II colorectal cancer prognosis. Gut 61:1560-1567, 2012
10. Zhang JX, Song W, Chen ZH, et al: Prognostic and predictive value of a microRNA signature in stage II colon cancer: A microRNA expression analysis. Lancet Oncol 14:1295-1306, 2013
11. Kerr P, Black J, von Frese J, et al: Molecular profiling from FFPE tissue: Stratification of the stage II colorectal cancer population. Mol Cancer Ther 6: 3751S, 2007 (abstr C138)
12. Plamadeala V, Huang S, McCreary SM, et al: Analytical performance of a formalin-fixed paraffinembedded tissue-based 634-probe prognostic assay for predicting outcome of patients with stage II colon cancer. Appl Immunohistochem Mol Morphol 22: 308-316, 2014
13. Niedzwiecki D, Bertagnolli MM, Warren RS, et al: Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after randomization of adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol 29:3146-3152, 2011
14. Prentice RL: A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 73:1-11, 1986
15. Gray RJ: Weighted analyses for cohort sampling designs. Lifetime Data Anal 15:24-40, 2009
16. Borgan O, Langholz B, Samuelsen SO, et al: Exposure stratified case-cohort designs. Lifetime Data Anal 6:39-58, 2000
17. Cai J, Zeng D: Sample size and power calculation for case-cohort studies. Biometrics 60:1015-1024, 2004
18. Therneau TR: Package "survival." Repository CRAN. http://r-forge.r-project.org
19. Self S, Prentice RL: Asymptotic distribution theory and efficiency results for case-cohort studies. Ann Stat 16:64-81, 1988
20. BarlowWE,IchikawaL,RosnerD,etal:Analysisof case-cohort designs. J Clin Epidemiol 52:1165-1172, 1999
21. Benson AB 3rd, Hamilton SR. Path toward prognostication and prediction: An evolving matrix. J Clin Oncol 29:4599-4601, 2011
22. Quasar Collaborative Group, Gray R, Barnwell J, et al: Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 370:2020-2029, 2007
23. Moertel CG, Fleming TR, Macdonald JS, et al: Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 13:2936-2943, 1995